BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib mesylate has been used successfully to treat chronic myelogenous leukemia (CML) and is a selective inhibitor of small-molecule protein kinases, which, in the case of CML, target the BCR/ABL fusion protein kinase.